LLY news sentiment

#172Tone

TechStock²Direct company coverageStored article

Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope

Eli Lilly's shares are near a record high as the company files six lawsuits against alleged illegal sales of its experimental obesity drug, retatrutide. These legal actions aim to protect the drug's future market ahead of its planned U.S. submission in Q1 2027, given its strong Phase 3 efficacy data. The lawsuits are a proactive measure to safeguard its next major franchise, as current revenue drivers Mounjaro and Zepbound already contribute significantly to Lilly's earnings.

Life SciencesEarningsFinancial Markets

Published

13 Aug 2026 14:08

News subject

Regulatory and legal

Why this score

Positive financial language

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 2.9% · 0.5d old

Duplicates

1 consolidated

#250Tone

SemaforDirect company coverageStored article

Eli Lilly tries to stop GLP-1 copycats

Eli Lilly has filed six lawsuits against US companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide. The drugmaker emphasizes that retatrutide has not received FDA approval and carries significant risks. This action is part of Lilly's broader effort to combat copycat versions of its GLP-1 products, which are known for their benefits beyond diabetes, including effects on heart, kidney, sleep apnea, and addiction.

Life Sciences

Published

12 Aug 2026 22:38

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.6% · 1.1d old

Duplicates

1 consolidated

#340Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug

CLINICAL-TRIALSClinical TrialsLAWSUITSLawsuitsOBESITYObesity

Published

12 Aug 2026 17:24

News subject

Regulatory and legal

Why this score

Negative market reaction

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.4% · 1.3d old

Duplicates

1 consolidated

#437Tone

finance.yahoo.comDirect company coverageStored article

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi

CLINICAL-TRIALSClinical TrialsLAWSUITSLawsuitsPHARMAPharma

Published

12 Aug 2026 16:54

News subject

Regulatory and legal

Why this score

Negative financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.3% · 1.4d old

Duplicates

1 consolidated

#571Tone

RTTNewsDirect company coverageStored article

Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales

Eli Lilly has filed six lawsuits against U.S. companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide. The lawsuits target compounding pharmacies, medical spas, and online sellers, as retatrutide is still in Phase 3 clinical trials and not yet approved by the FDA. This action is part of Lilly's broader effort to combat the black market for weight-loss drugs, which has seen a surge in demand and increased interception by U.S. Customs and Border Protection.

Life Sciences

Published

12 Aug 2026 17:05

News subject

Regulatory and legal

Why this score

Operating growth

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 2.9% · 1.4d old

Duplicates

2 consolidated

#650Tone

Straight ArrowDirect company coverageStored article

Eli Lilly sues six companies for selling illegal versions of groundbreaking weight-loss drug

Eli Lilly has filed lawsuits against six companies for illegally selling unapproved versions of its experimental weight-loss drug, retatrutide, which is still in Phase 3 trials. The pharmaceutical giant asserts that these black-market products are unverified and potentially life-threatening, and has called on social media platforms, e-commerce sites, and payment processors to help combat the illicit activity. The drugmaker plans to seek FDA approval for retatrutide in early 2027, given its promising trial results.

Life Sciences

Published

12 Aug 2026 16:38

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.6% · 1.4d old

Duplicates

1 consolidated

#743Tone

BioPharma DiveDirect company coverageStored article

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Eli Lilly has filed six new lawsuits to combat the black-market sale of its experimental obesity medicine, retatrutide. The drugmaker is taking action against online merchants, clinics, compounders, and foreign companies that claim to offer versions of its highly anticipated weight loss drug before it has even received FDA approval. Lilly warns that these unauthorized substances pose significant dangers to consumers due to potential fakery, impurity, or incorrect dosing.

FDAFdaLife SciencesPHARMAPharmaREGULATION

Published

12 Aug 2026 15:08

News subject

Regulatory and legal

Why this score

Negative financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.2% · 1.4d old

Duplicates

2 consolidated

#850Tone

Fierce PharmaDirect company coverageStored article

Lilly takes 6 companies to court for selling retatrutide knockoffs

Eli Lilly has filed lawsuits against six companies in the United States for allegedly selling illegal, unapproved versions of its experimental weight-loss drug, retatrutide. These companies include compounding pharmacies, medical spas, and online sellers falsely claiming the knockoffs are for "research-use only." This action follows FDA warnings about unapproved versions of weight-loss drugs and Lilly's previous legal efforts against similar unauthorized sales of Mounjaro.

Life Sciences

Published

12 Aug 2026 14:38

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 1.2% · 1.5d old

Duplicates

1 consolidated

#950Tone

CNBCDirect company coverageStored article

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Eli Lilly has filed six lawsuits against U.S. companies for allegedly selling black-market versions of its experimental obesity drug, retatrutide, which is still in Phase 3 clinical trials and has not yet received regulatory approval. The company is targeting compounding pharmacies, medical spas, and online sellers, and has urged social media platforms, e-commerce sites, and payment processors to take stronger action against unauthorized sellers. Lilly emphasized that these unauthorized products are unverified and pose significant health risks to consumers.

Life SciencesFinance

Published

12 Aug 2026 10:11

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 1.6% · 1.6d old

Duplicates

1 consolidated

#1050Tone

CBS NewsDirect company coverageStored article

Eli Lilly takes aim at illicit market for its experimental weight-loss drug

Eli Lilly is suing six companies for selling unapproved versions of its experimental weight-loss drug, retatrutide, in an effort to curb a growing illicit market. Despite the drug still being in clinical trials, promising results have led to widespread unauthorized sales by telehealth firms, clinics, and online vendors. The drugmaker plans to seek regulatory approval in early 2027 but faces challenges from the illicit market.

Life SciencesFinance

Published

12 Aug 2026 10:00

News subject

Market update

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.6% · 1.6d old

Duplicates

1 consolidated

#1150Tone

The Washington PostDirect company coverageStored article

Eli Lilly sues vendors accused of hawking versions of its experimental GLP-1

Eli Lilly has filed six lawsuits against wellness vendors, accusing them of illegally selling versions of its experimental weight-loss drug, retatrutide. The company aims to combat the illicit online sales of what it describes as a potent experimental GLP-1 drug. This action comes amidst concerns about unauthorized versions of their medications being sold.

Life Sciences

Published

12 Aug 2026 09:54

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.5% · 1.7d old

Duplicates

1 consolidated

#1250Tone

PR NewswireDirect company coverageStored article

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Eli Lilly and Company has filed six new lawsuits and escalated its fight against the illegal black market for retatrutide, an investigational drug not yet approved for human use. The company urges social media platforms, e-commerce sites, payment processors, and regulators to collaborate in shutting down the sale of unapproved retatrutide products, which pose significant risks to patients. Lilly emphasizes that these unverified products are not medicine and are being sold illegally by various entities falsely claiming legitimacy.

CLINICAL-TRIALSClinical TrialsFDA-APPROVALFda ApprovalFinanceHEALTHCARE

Published

12 Aug 2026 09:08

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.7% · 1.7d old

Duplicates

2 consolidated

#1355Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator.

FDA-APPROVALFda ApprovalOBESITYObesityPHARMAPharma

Published

11 Aug 2026 19:07

News subject

Regulatory and legal

Why this score

Contract or approval won

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2% · 2.3d old

Duplicates

1 consolidated

#1440Tone

Investing News NetworkDirect company coverageStored article

Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Eli Lilly's valuation has exceeded US$1 trillion, driven by strong sales of its GLP-1 weight-loss and diabetes treatments, Mounjaro and Zepbound. In contrast, Novo Nordisk's shares have declined due to slowing US sales and a high reliance on a single therapeutic category, despite both companies raising their full-year profit outlooks. The article highlights Lilly's aggressive move into oral treatments and a recent legal victory for both pharmaceutical giants against an antitrust lawsuit.

EarningsLife SciencesFinancial Markets

Published

11 Aug 2026 16:38

News subject

Regulatory and legal

Why this score

Operating deterioration, Operating growth, Legal or regulatory risk

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 3.4% · 2.4d old

Duplicates

1 consolidated

#1550Tone

finance.yahoo.comDirect company coverageStored article

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo

FDA-APPROVALFda ApprovalHEALTHCAREHealthcarePHARMAPharma

Published

11 Aug 2026 15:12

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.1% · 2.4d old

Duplicates

1 consolidated

#1635Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial

CLINICAL-TRIALSClinical TrialsFINANCIAL RESULTSFinancial ResultsLAWSUITLawsuit

Published

11 Aug 2026 12:44

News subject

Regulatory and legal

Why this score

Legal or regulatory risk

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 1.7% · 2.5d old

Duplicates

1 consolidated

#1750Tone

PR NewswireDirect company coverageStored article

Veeva Vault CRM Selected by Eli Lilly and Company

Veeva Systems announced that Eli Lilly and Company (Lilly) has committed to using Veeva Vault CRM globally. This platform is part of the Vault CRM Suite, which supports an "agentic commercial" model leveraging AI to deliver medicines to more patients. Both companies expressed excitement about expanding their strategic collaboration to improve patient access to breakthrough medicines.

BIOTECHBiotechCRMCrmLife SciencesPHARMA

Published

11 Aug 2026 11:12

News subject

Market update

Why this score

No clear positive or negative phrase

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 0.3% · 2.6d old

Duplicates

2 consolidated

#1857Tone

Stock TitanDirect company coverageStored article

Eli Lilly Commits to Veeva CRM to Bring More Medicines to Patients

Veeva Systems announced that Eli Lilly and Company will deploy Veeva Vault CRM globally. This commitment expands their strategic relationship, utilizing Veeva's AI-enabled "agentic commercial" model to help bring new medicines to more patients. The announcement highlights the continued adoption of Veeva's cloud solutions by major life sciences companies.

Life SciencesTechnologyFinanceEarnings

Published

11 Aug 2026 11:03

News subject

Earnings

Why this score

Positive financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.4% · 2.6d old

Duplicates

1 consolidated

#1942Tone

MarketBeatDirect company coverageStored article

Eli Lilly and Company $LLY Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in Eli Lilly and Company (NYSE:LLY) by 3.9% in the second quarter, selling 27,617 shares. Despite this sale, Eli Lilly remains a significant holding for Handelsbanken Fonder AB, representing 2.3% of its portfolio. Other institutional investors, however, increased their positions in the company, while an Eli Lilly executive sold a notable number of shares under a pre-arranged trading plan.

EarningsFinancial MarketsLife SciencesFinance

Published

11 Aug 2026 10:30

News subject

Earnings

Why this score

Institutional or insider selling

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1.8% · 2.6d old

Duplicates

1 consolidated

#2067Tone

nasdaq.comDirect company coverageStored article

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory Agency (MHRA) on August 10, 2026, follows the U.S. FDA's approval in April 2026, positioning Foundayo as a key entrant in the competitive obesity and diabetes market. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist designed for convenient daily use without food or water restrictions. Clinical data

BIOTECHBiotechDIABETESDiabetesEARNINGSEarnings

Published

11 Aug 2026 07:30

News subject

Regulatory and legal

Why this score

Contract or approval won

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.9% · 2.8d old

Duplicates

1 consolidated

#2150Tone

WTHRDirect company coverageStored article

Historical marker dedicated in downtown Indy commemorating Eli Lilly and Company's founding

A historical marker has been dedicated in downtown Indianapolis to commemorate the founding of Eli Lilly and Company. The marker signifies the pharmaceutical giant's origins in the city.

Life Sciences

Published

11 Aug 2026 03:57

News subject

Market update

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.4% · 2.9d old

Duplicates

1 consolidated

#2250Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay

DIABETESDiabetesEARNINGSEarningsOBESITYObesity

Published

10 Aug 2026 23:20

News subject

Analyst action

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.6% · 3.1d old

Duplicates

1 consolidated

#2342Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl

FDAFdaMANUFACTURINGManufacturingOBESITY-DRUGSObesity Drugs

Published

10 Aug 2026 22:21

News subject

Market update

Why this score

Negative financial language

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.4% · 3.1d old

Duplicates

1 consolidated

#2450Tone

nasdaq.comDirect company coverageStored article

Why Eli Lilly Topped the Market Today

Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight

EUROPEEuropeMARKETSMarketsOBESITY-TREATMENTSObesity Treatments

Published

10 Aug 2026 22:13

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 0.9% · 3.1d old

Duplicates

1 consolidated

#2550Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthro

MANUFACTURINGManufacturingOBESITY-MARKETObesity MarketPHARMAPharma

Published

10 Aug 2026 21:39

News subject

Market update

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.3% · 3.2d old

Duplicates

1 consolidated

#2650Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 m

FDA-APPROVALFda ApprovalGLP-1Glp 1OBESITYObesity

Published

10 Aug 2026 19:35

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 1% · 3.2d old

Duplicates

1 consolidated

#2750Tone

TradingKeyDirect company coverageStored article

Eli Lilly and Co Stock (LLY) Moved Up by 3.48% on Aug 10: Drivers Behind the Movement

Eli Lilly and Co (LLY) saw its stock price rise by 3.48% due to an optimistic revision of its full-year guidance and successful resolution of manufacturing bottlenecks for its metabolic treatments. Favorable updates regarding its Alzheimer's drug reimbursement and Medicare coverage, alongside increased institutional investment, further bolstered its performance. The company's robust balance sheet and aggressive R&D investments are positioning it as a leader in global pharmaceutical innovation.

EarningsLife SciencesFinancial Markets

Published

10 Aug 2026 19:15

News subject

Earnings

Why this score

No clear positive or negative phrase

Company focus

Shared story · 78%

How it is used

Direct company coverage

Weighted influence

Low · 0.8% · 3.3d old

Duplicates

1 consolidated

#2850Tone

ReutersDirect company coverageStored article

Lilly's weight-loss pill gets UK regulator's nod

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Eli Lilly's Foundayo pill for weight management and type 2 diabetes, making it the first European country to do so. This once-daily GLP-1 tablet has been gaining traction in the U.S. since its April approval but is not currently available through the NHS in the UK, while still trailing behind Novo Nordisk's Wegovy.

Life SciencesFinance

Published

10 Aug 2026 12:39

News subject

Regulatory and legal

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.1% · 3.5d old

Duplicates

1 consolidated

#2950Tone

finance.yahoo.comDirect company coverageStored article

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

Published

10 Aug 2026 05:00

News subject

Market update

Why this score

No clear positive or negative phrase

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 0.2% · 3.9d old

Duplicates

1 consolidated

#3082Tone

finance.yahoo.comDirect company coverageStored article

Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook

Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused on how fast the obesity franchise is still expanding.Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook Bull Case: Weight Loss Demand Still Has Room To Run The headline number came from Mounjaro and Zepbound. Mounjaro revenue jumped 91% to $9.9 billion, while Zepbou

EARNINGSEarningsGUIDANCEGuidanceHEALTHCAREHealthcare

Published

09 Aug 2026 08:51

News subject

Earnings

Why this score

Guidance raised, Improving financial comparison

Company focus

Main company · 100%

How it is used

Direct company coverage

Weighted influence

Low · 2.4% · 4.7d old

Duplicates

1 consolidated